Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGEarly Phase 1INTERVENTIONAL

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.

Who May Be Eligible (Plain English)

Who May Qualify: - Age: 0-65 years old, diagnosed with sepsis - Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines) - Confirmed or suspected infection Who Should NOT Join This Trial: - Violation of medical ethics - Significant confounding factors likely to bias study outcomes - Poor adherence to the study protocol - Concurrent participation in other clinical trials - Specific medical conditions: 1. History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine) 2. Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders 3. History of hypersensitivity or severe adverse reactions to biological products 4. Imminent terminal status (e.g., septic shock, life expectancy \<7 days) 5. Foreseeable risk of medical errors or disputes during hospitalization 6. Active drug-resistant infections 7. History of malignancy at screening 8. Pregnancy, lactation, or plans for pregnancy within the next year Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age: 0-65 years old, diagnosed with sepsis * Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines) * Confirmed or suspected infection Exclusion Criteria: * Violation of medical ethics * Significant confounding factors likely to bias study outcomes * Poor adherence to the study protocol * Concurrent participation in other clinical trials * Specific medical conditions: 1. History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine) 2. Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders 3. History of hypersensitivity or severe adverse reactions to biological products 4. Imminent terminal status (e.g., septic shock, life expectancy \<7 days) 5. Foreseeable risk of medical errors or disputes during hospitalization 6. Active drug-resistant infections 7. History of malignancy at screening 8. Pregnancy, lactation, or plans for pregnancy within the next year

Treatments Being Tested

BIOLOGICAL

CD83-positive MSC

90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment

BIOLOGICAL

regulatory MSC

45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment

OTHER

control solution

45 patients are infused with equal volume of control solution and receive regulatory treatment

Locations (1)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Chongqing, Chongqing Municipality, China